Share-based Payment Arrangement, Expense of Aurinia Pharmaceuticals Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aurinia Pharmaceuticals Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Aurinia Pharmaceuticals Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,919,000, a 29% decline year-over-year.
  • Aurinia Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2024 was $31,596,000, a 30% decline from 2023.
  • Aurinia Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2023 was $45,311,000, a 40% increase from 2022.
  • Aurinia Pharmaceuticals Inc. annual Share-based Payment Arrangement, Expense for 2022 was $32,300,000, a 3.4% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aurinia Pharmaceuticals Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,919,000 -$2,408,000 -29% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q1 2025 $28,450,000 $5,440,000 -$3,146,000 -37% 01 Jan 2025 31 Mar 2025 10-Q 31 Jul 2025 2025 Q2
Q4 2024 $31,596,000 $6,097,000 -$5,671,000 -48% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $37,267,000 $8,327,000 -$3,481,000 -29% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $40,748,000 $8,586,000 -$3,682,000 -30% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $44,430,000 $8,586,000 -$881,000 -9.3% 01 Jan 2024 31 Mar 2024 10-Q 31 Jul 2025 2025 Q2
Q4 2023 $45,311,000 $11,768,000 +$4,866,000 +71% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $40,445,000 $11,808,000 +$3,488,000 +42% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $36,957,000 $12,268,000 +$2,213,000 +22% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $34,744,000 $9,467,000 +$2,444,000 +35% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $32,300,000 $6,902,000 -$1,675,000 -20% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $33,975,000 $8,320,000 +$1,228,000 +17% 01 Jul 2022 30 Sep 2022 10-Q 02 Nov 2023 2023 Q3
Q2 2022 $32,747,000 $10,055,000 +$2,302,000 +30% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $30,445,000 $7,023,000 -$798,000 -10% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $31,243,000 $8,577,000 +$3,432,000 +67% 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 $27,811,000 $7,092,000 +$2,481,000 +54% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $25,330,000 $7,753,000 +$3,551,000 +85% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $21,779,000 $7,821,000 +$4,325,000 +124% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $17,454,000 $5,145,000 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $4,611,000 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $4,202,000 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $3,496,000 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1

Aurinia Pharmaceuticals Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $31,596,000 -$13,715,000 -30% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $45,311,000 +$13,011,000 +40% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $32,300,000 +$1,057,000 +3.4% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $31,243,000 +$13,789,000 +79% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $17,454,000 +$10,040,000 +135% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $7,414,000 +$554,000 +8.1% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $6,860,000 01 Jan 2018 31 Dec 2018 10-K 24 Feb 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.